Another Affymetrix custom array is helping scientists looking to develop more effective treatments for malaria. The GNF Malaria Tiling Array, a high density tiling array of Plasmodium falciparum, ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories ...

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

The widely used Affymetrix Whole-Transcript Gene 1.0 ST (sense target) microarray platform, normally used to assay gene expression, can also be utilized to interrogate exon-specific splicing. A new ...

Collaboration to expand research and molecular breeding tools for enhancing plant, crop, and livestock production outcomes SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NASDAQ:AFFX), ...

Affymetrix Inc. announced that the US Food and Drug Administration (FDA) has granted regulatory clearance to its GCS3000Dx (GCSDx) platform for in vitro gene expression diagnostic testing. The ...

Nature uses a common framework when building organisms as different as yeast, worms, fruit flies, mice, and humans. This makes it possible for scientists to learn about how our own genes work by ...

The DNA marketplace is changing: the technology is maturing, whole human genome arrays, as well as those of model organisms, are beginning to make it onto the market, and researchers have more choices ...

ExonHit Therapeutics has announced a supply and service provider agreement to combine Affymetrix' GeneChip® microarray platform and ExonHit's alternative RNA splicing technologies and expertise.

Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...